Clinical Trial Update: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the oral CGRP receptor antagonist ubrogepant for menstrual migraine in adults, focusing on adverse events and changes in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Ubrelvy (ubrogepant)

Snippet

Sponsor: AbbVie | Conditions: Migraine | Phase 3 | Status: RECRUITING